De novo presentation of acute myeloid leukaemia (AML) expressing the Philadelphia (Ph) chromosomal abnormality is rare and is associated with a dismal prognosis. To date reported cases of Ph+ AML have expressed either the e13a2 or e14a2 BCR-ABL fusion transcripts. We report a unique case of de novo AML expressing the e6a2 fusion transcript and describe disease sensitivity to both Imatinib prior to allogeneic stem cell transplant (SCT) and Dasatinib for AML relapse after allogeneic SCT.
Abstract:
De novo presentation of acute myeloid leukaemia (AML) expressing the Philadelphia (Ph) chromosomal abnormality is rare and is associated with a dismal prognosis. To date reported cases of Ph+ AML have expressed either the e13a2 or e14a2 BCR-ABL fusion transcripts. We report a unique case of de novo AML expressing the e6a2 fusion transcript and describe disease sensitivity to both Imatinib prior to allogeneic stem cell transplant (SCT) and Dasatinib for AML relapse after allogeneic SCT.
Furthermore we report that sustained molecular remission has been achieved despite withdrawal of tyrosine kinase inhibitor therapy.
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Introduction:
More than 90% of patients with chronic myeloid leukemia (CML) have b2a2 (e13a2) and/or b3a2 (e14a2) BCR-ABL fusion transcripts, which are translated into the p210 bcr-abl protein. CML with p190 BCR-ABL (breakpoints in mbcr) or p230 BCR-ABL (breakpoints in µbcr) fusion genes (e1a2 and e19a2 transcripts, respectively) are less frequent. Further variant BCR-ABL rearrangements affecting other regions of the BCR gene have also been described. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] A very rare fusion transcript joining the first 6 exons of BCR to exon 2 of ABL (e6a2) has been reported in four cases of CML with an aggressive clinical course. [2] [3] [4] [5] More recently, this translocation has been reported in single cases of chronic myelomonocytic leukemia, 13 T-ALL 14 and acute basophilic leukemia. 15 We describe a unique case in which the e6a2 was found in a patient with de novo Ph + acute myeloid leukemia (AML). Despite the previously described poor prognosis of this rare group of patients, the current patient achieved sustained disease control with imatinib, reduced intensity allogeneic stem cell transplantation and subsequently dasitinib. b2a2 (e13a2) and b3a2 (e14a2) transcripts were used in addition to primers e1C
(BCR exon e1) and a2B (ABL exon a2) for detection the e1a2 (p190) transcript 16 .
Amplification products were visualised by ethidium bromide staining of agarose gels.
PCR products were column purified using the PCR-M kit (Viogene, Taipei, Taiwan) and were eluted in a 30µl volume, 6µl was treated with ExoSapIT (GE Healthcare, Despite remaining off all tyrosine kinase inhibitor (TKI) therapy for a total of 18 months, the patient remains in complete molecular remission, with normal peripheral blood counts, 100% donor chimerism and full resolution of myelofibrosis on bone marrow examination. There has been no GVHD.
Discussion
The presence of shorter BCR-ABL transcripts in CML have been associated with aggressive clinical phenotype and early transformation, perhaps due to the lack of important regulatory bcr sequences within the fusion proteins [2] [3] [4] [5] . The observed poor clinical outcome associated with e6a2 BCR-ABL protein is likely to be due to increased kinase activity due to the partial loss of the guanine exchange factor (GEF)/dbl-like domain, which is also completely absent in p190 BCR-ABL protein, and which mediates the interaction with several Ras-like G proteins involved in cell 
M 1 2 3 4 5 6 7 8 nr nt
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
